North America Antibody Drug Conjugates Market Forecast to 2030
North America Antibody Drug Conjugates Market Forecast to 2030 – Regional Analysis – By Technology (Cleavable Linker and Non-cleavable Linker), Application (Blood Cancer, Breast Cancer, Ovarian Cancer, Urothelial Cancer, and Others), and Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies)
$2,840 – $4,440
- Description
- Toplines
- Reasons for Buying
- Table of Contents
- List of Tables
- LIst of Figures
- List of Companies
- Reviews (0)
Description
Increasing FDA Approvals for ADCs Fuels the North America Antibody Drug Conjugates Market
According to an article, An Insight into FDA Approved Antibody-Drug Conjugates for Cancer Therapy, published in the National Library of Medicine in September 2021, there were eight approvals for ADC in 2017, and it increased to 11 in September 2021. The FDA has approved a few more ADCs, including Lumoxiti, till the end of November 2022. Worldwide, more than 50 biopharmaceutical companies are involved in developing ADCs. The companies have targeted mainly blood cancer and other cancer types, such as lung, bladder, and gynecological tumors. Additionally, in June 2021, Evercore, a US-based Investment Banking and Evercore ISI, estimated that by 2030, the companies will sell ADCs for over US$ 20 billion annually. The increasing approvals and commercialization of ADCs are leading to significant market growth. Below is a list of FDA-approved ADCs.
Table 1. List of FDA-Approved ADCs
Sr. No. Company Trade Name ADC Drug Cancer Type Approval Year
1 Pfizer/Wyeth Mylotarg Gemtuzumab ozogamicin Relapsed Acute Myelogenous Leukemia (AML) 2000; 2017
2 Seagen Genetics, Millennium/Takeda Adcetris Brentuximab vedotin Relapsed HL and Relapsed sALCL 2011
3 Genentech, Roche Kadcyla Trastuzumab emtansine HER2-positive Metastatic Breast Cancer (mBC) 2013
4 Pfizer/Wyeth Besponsa Inotuzumab ozogamicin Relapsed or Refractory CD22-positive B-cell Precursor Acute Lymphoblastic Leukemia 2017
5 Astrazeneca Lumoxiti Moxetumomab pasudotox Relapsed or refractory hairy cell leukaemia (HCL) in adults 2018
6 Genentech, Roche Polivy Polatuzumab vedotin-piiq Relapsed or refractory diffuse large B-cell lymphoma (DLBCL) 2019
7 Astellas/Seagen Genetics Padcev Enfortumab vedotin Metastatic urothelial cancer in adult who have received a PD-1 or PD-L1 inhibitor, and a Pt-containing therapy 2019
8 AstraZeneca/Daiichi Sankyo Enhertu Trastuzumab deruxtecan Metastatic HER2-positive breast cancer in adults, received two or more prior anti-HER2 based regimens 2019
9 Immunomedics Trodelvy Sacituzumab govitecan Metastatic triple-negative breast cancer (mTNBC) in adults, and patients received minimum two prior therapies for patients with relapsed or refractory metastatic disease 2020
10 GlaxoSmithKline (GSK) Blenrep Belantamab mafodotin-blmf Relapsed or refractory multiple myeloma in adults 2020, withdrawn on 22 Nov. 2022 in the US.
11 ADC Therapeutics Zynlonta Loncastuximab tesirine-lpyl Large B-cell lymphoma 2021
12 Seagen Inc Tivdak Tisotumab vedotin-tftv Recurrent or metastatic cervical cancer 2021
13 ImmunoGen Elahere Mirvetuximab soravtansine Platinum-resistant ovarian cancer 2022
North America Antibody Drug Conjugates Market Overview
The antibody drug conjugates (ADCs) market in North America is analyzed based on the US, Canada, and Mexico. The market growth in the region is attributed to increasing research and development for ADCs, rising product approvals, growing awareness about ADCs, and rising number of mergers, collaborations, and partnerships among the operating players. In addition, significantly growing incidences of cancer are among the other leading factors escalating the demand for ADCs.
Furthermore, growing partnerships among the companies to expand their technologies in different regions enable market growth. In August 2023, ImmunoGen, Inc. and Takeda Pharmaceutical Company Limited collaborated to develop and commercialize ELAHERE, Immunogens ADC therapy, in Japan. Under the collaboration agreement, ImmunoGen, Inc. receives upfront and additional payments upon conversion of FDA accelerated approval of ELAHERE to treat platinum-resistant ovarian cancer. If Takeda achieves certain regulatory and commercial milestones and double-digit royalties through the net sales of ELAHERE in Japan, it will pay an additional payment to ImmunoGen, Inc. Nevertheless, Immunogen has retained its exclusive production rights and will supply the product for development and commercialization in Japan. In return, Takeda will be responsible for all regulatory filing and have an exclusive license to develop and commercialize ELAHERE in Japan.
North America Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Million)
North America Antibody Drug Conjugates Market Segmentation
The North America antibody drug conjugates market is segmented based on technology, application, distribution channel, and country.
Based on technology, the North America antibody drug conjugates market antibody drug conjugates market is bifurcated into cleavable linker and non-cleavable linker. The cleavable linker segment held a larger share in 2022.
Based on application, the North America antibody drug conjugates market antibody drug conjugates market is segmented into blood cancer, breast cancer, ovarian cancer, urothelial cancer, and others. The breast cancer segment held the largest share in 2022.
Based on distribution channel, the North America antibody drug conjugates market antibody drug conjugates market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies. The hospital pharmacies segment held the largest share in 2022.
Based on country, the North America antibody drug conjugates market is categorized into US, Canada, and Mexico. The US dominated the North America antibody drug conjugates market in 2022.
ADC Therapeutics SA, Pfizer Inc, Hoffmann-La Roche Ltd, ImmunoGen, Inc, GSK Plc, Gilead Sciences Inc, AstraZeneca Plc, Astellas Pharma Inc, RemeGen Co Ltd, and Takeda Pharmaceutical Co Ltd are some of the leading companies operating in the North America antibody drug conjugates market.
Summary Info
| Industry: | |
|---|---|
| Pricing options: | |
| Geographical coverage: | |
| Year of Publication: |
According to the Research Team’ research, the North America antibody drug conjugates market was valued at US$ 3,659.81 million in 2022 and is expected to reach US$ 13,681.58 million by 2030, registering a CAGR of 17.9% from 2022 to 2030. Growing strategic partnerships to develop antibody drug conjugates and rising incidences of cancer are among the critical factors attributed to the North America antibody drug conjugates market expansion.
Antibody-drug conjugates (ADCs) have received significant attention worldwide for cancer therapy. Since the approval of Mylotarg (Pfizer, Inc.’s first ADC) by the US Food and Drug Administration (FDA) in 2000, there has been substantial growth in strategic decisions by pharmaceutical leaders despite the COVID-19 pandemic. In 2020, various pharmaceutical companies entered into partnerships to develop ADCs. For instance, in July 2020, AstraZeneca and Daiichi Sankyo collaborated to develop and commercialize DS-1062. DS-1602 is Daiichi Sankyos proprietary trophoblast cell-surface antigen 2 (TROP2)-directed ADC to treat multiple tumor types.
Likewise, in December 2022, Merck & Co., Inc. (MSD) and Kelun-Biotech, a Sichuan Kelun Pharmaceutical Co., Ltd. subsidiary, partnered to develop seven investigational preclinical ADCs to treat cancer. Under the agreement, MSD received a grant for exclusive global licenses from Kelun Biotech to research, develop, manufacture, and commercialize multiple investigational preclinical ADC therapies. In addition, MSD has exclusive options to obtain additional licenses for ADC candidates.
Similarly, in April 2023, BioNTech SE and Duality Biologics (Suzhou) Co. Ltd signed a strategic partnership agreement to develop next-generation ADCs to treat cancer and autoimmune diseases. Under the partnership agreement, BioNTech SE will have access to DualityBios lead candidate, DB-1303. DB-1303 is a topoisomerase-1 inhibitor-based ADC directed against Human Epidermal Growth Factor Receptor 2 (HER2). HER2 is an overexpressed common target in most cancer types and contributes to cancer cells aggressive growth and spread. Secondly, BioNTech SE will have access to another topoisomerase-1 inhibitor-based ADC candidate, DB-1311. Companies have aimed to transform and commercialize innovative therapies worldwide.
On the contrary, high cost of ADCs development and commercialization hampers the growth North America antibody drug conjugates market.
Based on technology, the North America antibody drug conjugates market is bifurcated into cleavable linker and non-cleavable linker. The cleavable linker segment held 69.8% share of the North America antibody drug conjugates market in 2022, amassing US$ 2,553.86 million. It is projected to garner US$ 9,427.84 million by 2030 to expand at 17.7% CAGR during 2022-2030.
Based on application, the North America antibody drug conjugates market is segmented into blood cancer, breast cancer, ovarian cancer, urothelial cancer, and others. The breast cancer segment held 53.6% share of the North America antibody drug conjugates market in 2022, amassing US$ 1,960.06 million. It is projected to garner US$ 7,551.09 million by 2030 to expand at 18.4% CAGR during 2022-2030.
Based on distribution channel, the North America antibody drug conjugates market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies. The hospital pharmacies segment held 66.2% share of North America antibody drug conjugates market in 2022, amassing US$ 2,421.99 million. It is projected to garner US$ 9,280.83 million by 2030 to expand at 18.3% CAGR during 2022-2030.
Based on country, the North America antibody drug conjugates market is categorized into US, Canada, and Mexico. The US held 86.6% share of North America antibody drug conjugates market in 2022, amassing US$ 3,167.57 million. It is projected to garner US$ 12,162.92 million by 2030 to expand at 18.3% CAGR during 2022-2030.
Key players operating in the North America antibody drug conjugates market are ADC Therapeutics SA, Pfizer Inc, Hoffmann-La Roche Ltd, ImmunoGen, Inc, GSK Plc, Gilead Sciences Inc, AstraZeneca Plc, Astellas Pharma Inc, RemeGen Co Ltd, and Takeda Pharmaceutical Co Ltd, among others.
– In Mar 2023, Pfizer Inc. and Seagen Inc entered into a definitive merger agreement under which Pfizer will acquire Seagen, a global biotechnology company that discovers, develops, and commercializes transformative cancer medicines, for $229 in cash per Seagen share for a total enterprise value of $43 billion.
– In Sept 2023, Seagen Inc., a world leader and pioneer in antibody-drug conjugate (ADC) therapies, and RemeGen Co., Ltd. have entered into an exclusive worldwide licensing agreement to develop and commercialize disitamab vedotin, a novel HER2-targeted ADC. This collaboration leverages Seagens world-class expertise and knowledge of ADC development, manufacturing, and commercialization to maximize the potential of disitamab vedotin.
o Highlights key business priorities in order to assist companies to realign their business strategies.
o The key findings and recommendations highlight crucial progressive industry trends in North America antibody drug conjugates market, thereby allowing players across the value chain to develop effective long-term strategies.
o Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
o Scrutinize in-depth North America market trends and outlook coupled with the factors driving the market, as well as those hindering it.
o Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing, and distribution
TABLE OF CONTENTS
1.1 the Research Team Research Report Guidance
1.2 Market Segmentation
2. Executive Summary
2.1 Market Attractiveness
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. North America Antibody Drug Conjugates Market – Key Industry Dynamics
4.1 Key Market Drivers:
4.1.1 Growing Strategic Partnerships to Develop Antibody Drug Conjugates
4.1.2 Rising Incidences of Cancer Cases
4.1.3 Increasing FDA Approvals for ADCs
4.2 Market Restraints
4.2.1 High Cost of ADCs Development and Commercialization
4.3 Market Opportunities
4.3.1 Increasing Investments to Develop ADCs
4.4 Market Trends
4.4.1 Escalating Pipeline of ADCs
4.5 Impact Analysis:
5. Antibody Drug Conjugates Market – North America Market Analysis
5.1 North America Antibody Drug Conjugates Market Revenue (US$ Mn), 2017 – 2030
6. North America Antibody Drug Conjugates Market – Revenue and Forecast to 2030 – by Technology
6.1 Overview
6.2 North America Antibody Drug Conjugates Market Revenue Share, by Technology 2022 & 2030 (%)
6.3 Cleavable Linker
6.3.1 Overview
6.3.2 Cleavable Linker: North America Antibody Drug Conjugates Market – Revenue and Forecast to 2030 (US$ Million)
6.4 Non-cleavable Linker
6.4.1 Overview
6.4.2 Non-cleavable Linker: North America Antibody Drug Conjugates Market – Revenue and Forecast to 2030 (US$ Million)
7. North America Antibody Drug Conjugates Market – Revenue and Forecast to 2030 – by Application
7.1 Overview
7.2 North America Antibody Drug Conjugates Market Revenue Share, by Application 2022 & 2030 (%)
7.3 Blood Cancer
7.3.1 Overview
7.3.2 Blood Cancer: North America Antibody Drug Conjugates Market – Revenue and Forecast to 2030 (US$ Million)
7.4 Breast Cancer
7.4.1 Overview
7.4.2 Breast Cancer: North America Antibody Drug Conjugates Market – Revenue and Forecast to 2030 (US$ Million)
7.5 Ovarian Cancer
7.5.1 Overview
7.5.2 Ovarian Cancer: North America Antibody Drug Conjugates Market – Revenue and Forecast to 2030 (US$ Million)
7.6 Urothelial Cancer
7.6.1 Overview
7.6.2 Urothelial Cancer: North America Antibody Drug Conjugates Market – Revenue and Forecast to 2030 (US$ Million)
7.7 Others
7.7.1 Overview
7.7.2 Others: North America Antibody Drug Conjugates Market – Revenue and Forecast to 2030 (US$ Million)
8. North America Antibody Drug Conjugates Market – Revenue and Forecast to 2030 – by Distribution Channel
8.1 Overview
8.2 North America Antibody Drug Conjugates Market Revenue Share, by Distribution Channel 2022 & 2030 (%)
8.3 Hospital Pharmacies
8.3.1 Overview
8.3.2 Hospital Pharmacies: North America Antibody Drug Conjugates Market – Revenue and Forecast to 2030 (US$ Million)
8.4 Retail Pharmacies
8.4.1 Overview
8.4.2 Retail Pharmacies: North America Antibody Drug Conjugates Market – Revenue and Forecast to 2030 (US$ Million)
8.5 Online Pharmacies
8.5.1 Overview
8.5.2 Online Pharmacies: North America Antibody Drug Conjugates Market – Revenue and Forecast to 2030 (US$ Million)
9. North America Antibody Drug Conjugates Market – Country Analysis
9.1 North America Antibody Drug Conjugates Market, Revenue and Forecast To 2030
9.1.1 Overview
9.1.2 North America Antibody Drug Conjugates Market Breakdown, by Country Revenue (2022) (US$ Million)
9.1.3 North America: Antibody Drug Conjugates Market, by Countries,2022 and 2030 (%)
9.1.3.1 US
9.1.3.1.1 Overview
9.1.3.1.2 US: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)
9.1.3.1.3 US: Antibody Drug Conjugates Market, by Technology
9.1.3.1.4 US: Antibody Drug Conjugates Market, by Application
9.1.3.1.5 US: Antibody Drug Conjugates Market, by Distribution Channel
9.1.3.2 Canada
9.1.3.2.1 Overview
9.1.3.2.2 Canada: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)
9.1.3.2.3 Canada: Antibody Drug Conjugates Market, by Technology
9.1.3.2.4 Canada: Antibody Drug Conjugates Market, by Application
9.1.3.2.5 Canada: Antibody Drug Conjugates Market, by Distribution Channel
9.1.3.3 Mexico
9.1.3.3.1 Overview
9.1.3.3.2 Mexico: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)
9.1.3.3.3 Mexico: Antibody Drug Conjugates Market, by Technology
9.1.3.3.4 Mexico: Antibody Drug Conjugates Market, by Application
9.1.3.3.5 Mexico: Antibody Drug Conjugates Market, by Distribution Channel
10. Antibody Drug Conjugates Market-Industry Landscape
10.1 Overview
10.2 Organic Growth Strategies
10.2.1 Overview
10.3 Inorganic Growth Strategies
10.3.1 Overview
10.4 Companies’ Manufacturing Capacities and Capabilities
11. Company Profiles
11.1 ADC Therapeutics SA
11.1.1 Key Facts
11.1.2 Business Description
11.1.3 Products and Services
11.1.4 Financial Overview
11.1.5 SWOT Analysis
11.1.6 Key Developments
11.2 Pfizer Inc
11.2.1 Key Facts
11.2.2 Business Description
11.2.3 Products and Services
11.2.4 Financial Overview
11.2.5 SWOT Analysis
11.2.6 Key Developments
11.3 Hoffmann-La Roche Ltd
11.3.1 Key Facts
11.3.2 Business Description
11.3.3 Products and Services
11.3.4 Financial Overview
11.3.5 SWOT Analysis
11.3.6 Key Developments
11.4 ImmunoGen, Inc.
11.4.1 Key Facts
11.4.2 Business Description
11.4.3 Products and Services
11.4.4 Financial Overview
11.4.5 SWOT Analysis
11.4.6 Key Developments
11.5 GSK Plc
11.5.1 Key Facts
11.5.2 Business Description
11.5.3 Products and Services
11.5.4 Financial Overview
11.5.5 SWOT Analysis
11.5.6 Key Developments
11.6 Gilead Sciences Inc
11.6.1 Key Facts
11.6.2 Business Description
11.6.3 Products and Services
11.6.4 Financial Overview
11.6.5 SWOT Analysis
11.6.6 Key Developments
11.7 AstraZeneca Plc
11.7.1 Key Facts
11.7.2 Business Description
11.7.3 Products and Services
11.7.4 Financial Overview
11.7.5 SWOT Analysis
11.7.6 Key Developments
11.8 Astellas Pharma Inc
11.8.1 Key Facts
11.8.2 Business Description
11.8.3 Products and Services
11.8.4 Financial Overview
11.8.5 SWOT Analysis
11.8.6 Key Developments
11.9 RemeGen Co Ltd
11.9.1 Key Facts
11.9.2 Business Description
11.9.3 Products and Services
11.9.4 Financial Overview
11.9.5 SWOT Analysis
11.9.6 Key Developments
11.10 Takeda Pharmaceutical Co Ltd
11.10.1 Key Facts
11.10.2 Business Description
11.10.3 Products and Services
11.10.4 Financial Overview
11.10.5 SWOT Analysis
11.10.6 Key Developments
12. Appendix
12.1 About Us
12.2 Glossary of Terms
LIST OF TABLES
Table 1. North America Antibody Drug Conjugates Market Segmentation
Table 2. New Cancer Cases Worldwide, in 2020
Table 3. List of FDA-Approved ADCs
Table 4. US: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) – Technology
Table 5. US: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) – Application
Table 6. US: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) – Distribution Channel
Table 7. Canada: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) – Technology
Table 8. Canada: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) – Application
Table 9. Canada: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) – Distribution Channel
Table 10. Mexico: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) – Technology
Table 11. Mexico: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) – Application
Table 12. Mexico: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) – Distribution Channel
Table 13. Recent Organic Growth Strategies in Antibody Drug Conjugates Market
Table 14. Recent Inorganic Growth Strategies in the Antibody Drug Conjugates Market
Table 15. Glossary of Terms, Antibody Drug Conjugates Market
LIST OF FIGURES
Figure 1. North America Antibody Drug Conjugates Market Segmentation, By Country
Figure 2. Key Insights
Figure 3. North America Antibody Drug Conjugates Market – Key Industry Dynamics
Figure 4. Impact Analysis of Drivers and Restraints
Figure 5. North America Antibody Drug Conjugates Market Revenue (US$ Mn), 2017 – 2030
Figure 6. North America Antibody Drug Conjugates Market Revenue Share, by Technology 2022 & 2030 (%)
Figure 7. Cleavable Linker: North America Antibody Drug Conjugates Market – Revenue and Forecast to 2030 (US$ Million)
Figure 8. Non-Cleavable Linker: North America Antibody Drug Conjugates Market – Revenue and Forecast to 2030 (US$ Million)
Figure 9. North America Antibody Drug Conjugates Market Revenue Share, by Application 2022 & 2030 (%)
Figure 10. Blood Cancer: North America Antibody Drug Conjugates Market – Revenue and Forecast to 2030 (US$ Million)
Figure 11. Breast Cancer: North America Antibody Drug Conjugates Market – Revenue and Forecast to 2030 (US$ Million)
Figure 12. Ovarian Cancer: North America Antibody Drug Conjugates Market – Revenue and Forecast to 2030 (US$ Million)
Figure 13. Urothelial Cancer: North America Antibody Drug Conjugates Market – Revenue and Forecast to 2030 (US$ Million)
Figure 14. Others: North America Antibody Drug Conjugates Market – Revenue and Forecast to 2030 (US$ Million)
Figure 15. North America Antibody Drug Conjugates Market Revenue Share, by Distribution Channel 2022 & 2030 (%)
Figure 16. Hospital Pharmacies: North America Antibody Drug Conjugates Market – Revenue and Forecast to 2030 (US$ Million)
Figure 17. Retail Pharmacies: North America Antibody Drug Conjugates Market – Revenue and Forecast to 2030 (US$ Million)
Figure 18. Online Pharmacies: North America Antibody Drug Conjugates Market – Revenue and Forecast to 2030 (US$ Million)
Figure 19. North America Antibody Drug Conjugates, by Key Country – Revenue (2022) (US$ Million)
Figure 20. North America: Antibody Drug Conjugates Market, By Key Countries, 2022 and 2030 (%)
Figure 21. US: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)
Figure 22. Canada: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)
Figure 23. Mexico: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)
The List of Companies – North America Antibody Drug Conjugates Market
1. ADC Therapeutics SA
2. Pfizer Inc
3. Hoffmann-La Roche Ltd
4. ImmunoGen Inc
5. GSK Plc
6. Gilead Sciences Inc
7. AstraZeneca Plc
8. Astellas Pharma Inc
9. RemeGen Co Ltd
10. Takeda Pharmaceutical Co Ltd
You must be logged in to post a review.
Reviews
There are no reviews yet.